


Adult (age≥18 years) excluded high cost drug treatment pathway for active Crohn's disease- based on NICE TAs [187](#), [352](#), [456](#), [888](#) & [905](#)



Refer to individual [SPC's](#) for full prescribing information including dose restrictions, adverse drug reactions, contraindications and cautions; and to [Drug Safety Updates](#) for latest drug safety notices.
Note: dose escalation is not routinely commissioned unless specified in the pathway.

Version	1.0
Developed by	Pharmacy and Medicines Optimisation Team, Hertfordshire and West Essex (HWE) ICB with relevant HWE ICS stakeholders.
Approved by	Hertfordshire & West Essex Area Prescribing Committee
Date approved / updated	July 2023
Review Date	This HWE APC recommendation is based upon the evidence available at the time of publication. This recommendation will be reviewed upon request in the light of new evidence becoming available.
Superseded versions	Adult (age≥18 years) biologics treatment pathway for active Crohn's disease- based on NICE TAs 187, 352 & 456. HMMC, Oct 2020 Adult (age≥18 years) biologics treatment pathway for active Crohn's disease- based on NICE TAs 187, 352 & 456 update Feb 2020. West Essex CCG MOPB, Feb 2020